Results 101 to 110 of about 1,496,473 (269)
Structure‐forward targeting of claudins with synthetic binders
FEBS Letters, EarlyView.Claudins form the paracellular barriers between epithelial and endothelial tissues at tight junctions and are targets for molecular binders with the goal of modulating barrier permeability. Claudin‐binding molecules are relevant in drug delivery or in altering claudin interactions with disease‐causing proteins.
Alex J. Vecchio
wiley +1 more source
Antiplatelet therapy in acute coronary syndromes: current agents and impact on patient outcomes
Patient Related Outcome Measures, 2010 Hussam M Tayeb, Adam J Nelson, Scott R Willoughby, Matthew I WorthleyCardiovascular Research Centre, Royal Adelaide Hospital and Discipline of Medicine, University of Adelaide, Adelaide, South Australia, AustraliaAbstract: Platelets play a central role ...
Hussam M Tayeb +3 more
doaj
Discerning protein pools by selective staining with self‐labeling tags
FEBS Letters, EarlyView.Cell surface proteins have an intra‐ and extracellular pool. Combining genetic fusion to self‐labeling tags that can be addressed with small molecule fluorophores allows separating these pools. We highlight recent developments and techniques for state‐of‐the‐art interrogation of cell surface proteins in the complex tissue setting.
Kati Fischermanns, Johannes Broichhagen
wiley +1 more source
Patient Related Outcome Measures, 2013 Michael Prugger, Thomas Berger Neuroimmunology and Multiple Sclerosis Clinic and Research Unit, Clinical Department of Neurology, Innsbruck Medical University, Innsbruck, Austria Purpose: To assess the long-term effects of prolonged-release (PR ...
Prugger M, Berger T
doaj
FEBS Letters, EarlyView.Animals must match their growth rate to available nutrients. We show that in Drosophila larvae, the nutrient‐sensing TOR kinase controls growth by regulating levels of TFAM, a key regulator of mitochondrial function, in the adipose tissue. When nutrients are abundant, high TOR activity suppresses TFAM, lowering mitochondrial bioenergetic activity and ...
Shrivani Sriskanthadevan‐Pirahas +4 more
wiley +1 more source
Patient Related Outcome Measures, 2015 Chloe Tolley,1 Diana Rofail,2 Adam Gater,1 Justine K Lalonde31Adelphi Values Ltd, Bollington, UK; 2Roche Products Ltd, Welwyn Garden City, UK; 3Roche S.A.S, Paris, France Abstract: Many clinical outcome assessments (COAs) were originally developed ...
Tolley C, Rofail D, Gater A, Lalonde JK
doaj
Peripheral lysosomes recruit PLEKHG3 to focal adhesions and restrain protrusion dynamics
FEBS Letters, EarlyView.Proximity‐dependent labeling at the LAMTOR complex revealed the Rho GEF PLEKHG3 as a lysosome‐proximal protein directing the study toward the influence of lysosome positioning on actin dynamics and cell motility. We show that PLEKHG3 colocalizes with lysosomes at focal adhesion sites and observe that forced peripheral dispersion of lysosomes hinders ...
Rainer Ettelt +8 more
wiley +1 more source
Engineering peptides into antibodies—opportunities and strategies for therapeutic innovation
FEBS Letters, EarlyView.Peptides and antibodies occupy complementary therapeutic niches. Peptides recognize difficult targets in a compact format, while antibodies add specificity, long half‐life, and effector functions. This review examines strategies that merge both modalities—peptide grafting into loops, terminal and Fc fusions, and bioconjugation—highlighting how ...
Jinling Wang +2 more
wiley +1 more source
Patient Related Outcome Measures, 2011 Artavazd Tadevosyan1, Eric J MacLaughlin2, Vardan T Karamyan31Departments of Medicine, Montreal Heart Institute and Université de Montréal, Montreal, QC, Canada; 2Department of Pharmacy Practice, 3Department of Pharmaceutical ...
Artavazd Tadevosyan +2 more
doaj
Epigenetic reprogramming of lineage switching in cancer
FEBS Letters, EarlyView.Cancer cells rarely commit to a single identity. Epigenetic mechanisms and tumor microenvironment cues push epithelial cells toward flexible, hybrid states that can shift into mesenchymal, neuroendocrine, or stem‐like fates, driving metastasis, drug resistance, and tumor heterogeneity. Targeting the epigenetic regulators behind these transitions, using
Ezgi Boyvatlı +4 more
wiley +1 more source